'Made in India' Covaxin gets SEC nod for emergency use
By Asianet Newsable English | First Published Jan 2, 2021, 9:14 PM ISTThe Government-appointed expert panel has recommended granting permission for restricted emergency use authorisation for Bharat Biotech's indigenously developed COVID-19 vaccine Covaxin.
The Government-appointed expert panel has recommended granting permission for restricted emergency use authorisation for Bharat Biotech's indigenously developed COVID-19 vaccine Covaxin.
The Special Experts Committee, which reviewed Bharat Biotech's application gave a favourable report to the Drugs Controller General of India.
Latest Videos
The DCGI is expected to give its decision on the applications for the COVID-19 vaccine candidates on Sunday.
The vaccine: Covaxin is an indigenous inactivated two-dose SARS-CoV2 vaccine developed by Bharat Biotech along with the Indian Council of Medical Research and the National Institute of Virology. The vaccine has been developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) bio-containment facility
Efficacy: According to Bharat Biotech, once the vaccine is injected into a human, it "has no potential to infect or replicate, since it is a killed virus". "It just serves to the immune system as a dead virus and mounts an antibody response towards the virus."
Storage: BBV152 or Covaxin is stored between 2 Degree Celsius and 8 Degree Celsius, which is compatible with all national immunization program cold chain requirements.
subscribe to Asianet Newsable WhatsApp channel by clicking here. For more reliable and latest news
subscribe to Asianet Newsable Telegram channel by clicking here.